Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells

BMB Reports

Volumn 47, Issue 4, 2014, Pages 221-226

  Shi, Xinli ^a,b   Liu, Jingli ^c   Ren, Laifeng ^a   Mao, Nan ^a   Tan, Fang ^a   Ding, Nana ^a   Yang, Jing ^a   Li, Mingyuan ^a,d  

^a SICHUAN UNIVERSITY   (China)

^b HEBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^c Department of Medical Imaging   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Human hepatocellular carcinoma; Nutlin 3; P53

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NUTLIN 3; PHOSPHOSERINE; PIPERAZINE DERIVATIVE; PROTEIN P53;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; PHOSPHORYLATION; PHOSPHOSERINE; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899650084     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.4.146     Document Type: Article

References (34)

1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA- Cancer J. Clin. 61, 69-90.
2. Farazi, P. A. and DePinho, R. A. (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687.
3. Petitjean, A., Achatz, M., Borresen-Dale, A., Hainaut, P. and Olivier, M. (2007) TP53 mutations in human cancers:functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165.
4. Lee, S. H. (2001) Structural Origin for the Transcriptional Activity of Human p 53. BMB Rep. 34, 73-79.
5. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
6. Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R. and Gu, W. (2003) Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975.
7. Vousden, K. H. and Lane, D. P. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Bio. 8, 275-283.
8. Kruse, J. P. and Gu, W. (2008) SnapShot: p53 posttranslational modifications. Cell 133, 930.
9. Cox, M. L. and Meek, D. W. (2010) Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell. Signal. 22, 564-571.
10. Yap, D. B. S., Hsieh, J. K., Zhong, S., Heath, V., Gusterson, B., Crook, T. and Lu, X. (2004) Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res. 64, 4749-4754.
11. Sakaguchi, K., Sakamoto, H., Lewis, M. S., Anderson, C. W., Erickson, J. W., Appella, E. and Xie, D. (1997) Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36, 10117-10124.
12. Achison, M. and Hupp, T. R. (2003) Hypoxia attenuates the p53 response to cellular damage. Oncogene 22, 3431-3440.
13. Matsumoto, M., Furihata, M., Kurabayashi, A., Sasaguri, S., Araki, K., Hayashi, H. and Ohtsuki, Y. (2004) Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 67, 143-150.
14. Bar, J. K., Slomska, I., Rabczynki, J., Noga, L. and Grybos, M. (2009) Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int. J. Gynecol. Cancer 19, 1322-1328.
15. Kim, Y. Y., Park, B. J., Kim, D. J., Kim, W. H., Kim, S., Oh, K. S., Lim, J. Y., Kim, J., Park, C. and Park, S. I. (2004) Modification of serine 392 is a critical event in the regulation of p53 nuclear export and stability. FEBS Lett. 572, 92-98.
16. Muller, P. A. and Vousden, K. H. (2013) p53 mutations in cancer. Nat. Cell Biol. 15, 2-8.
17. Radhakrishnan, S. K. and Gartel, A. L. (2006) CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell cycle 5, 519-521.
18. Cozza, G., A Pinna, L. and Moro, S. (2013) Kinase CK2 Inhibition: An Update. Curr. Med. Chem. 20, 671-693.
19. Shangary, S. and Wang, S. (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. 49, 223-241.
20. Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V. and Gudkov, A. V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737.
21. D Amaral, J., M Xavier, J., J Steer, C. and MP Rodrigues, C. (2010) Targeting the p53 pathway of apoptosis. Curr. Pharm. Design 16, 2493-2503.
22. Ashcroft, M., Kubbutat, M. H. and Vousden, K. H. (1999) Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19, 1751-1758.
23. Sullivan, K. D., Gallant-Behm, C. L., Henry, R. E., Fraikin, J.-L. and Espinosa, J. M. (2012) The p53 circuit board. BBA-Rev. Cancer 1825, 229-244.
24. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C. and Klein, C. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
25. Guan, Y.-S., La, Z., Yang, L., He, Q. and Li, P. (2007) p53 gene in treatment of hepatic carcinoma: status quo. World J. Gastroentero. 13, 985-992.
26. Hanel, W. and Moll, U. M. (2012) Links between mutant p53 and genomic instability. J. Cell. Biochem. 113, 433-439.
27. Gillotin, S., Yap, D. and Lu, X. (2010) Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Cell Cycle 9, 1390-1398.
28. Furlan, A., Stagni, V., Hussain, A., Richelme, S., Conti, F., Prodosmo, A., Destro, A., Roncalli, M., Barila, D. and Maina, F. (2011) Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ. 18, 1608-1616.
29. Fan, G., Ma, X., Wong, P., Rodrigues, C. and Steer, C. (2004) p53 dephosphorylation and p21Cip1/Waf1 translocation correlate with caspase-3 activation in TGF-ß1-induced apoptosis of HuH-7 cells. Apoptosis 9, 211-221.
30. Matsumoto, M., Furihata, M. and Ohtsuki, Y. (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med. Mol. Morphol. 39, 79-87.
31. Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R. and Ball, K. L. (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. cell 23, 251-263.
32. Wang, J., Zheng, T., Chen, X., Song, X., Meng, X., Bhatta, N., Pan, S., Jiang, H. and Liu, L. (2011) MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. J. Gastroen. Hepatol. 26, 371-377.
33. Yu, Y., Gu, Z., Yin, J., Chou, W., Kwok, C., Qin, Z. and LIANG, Z. (2010) Ursolic acid induces human hepatoma cell line SMMC-7721 apoptosis via p53-dependent pathway. Chinese Med. J. 123, 1915-1923.
34. Cai, X., Ye, T., Liu, C., Lu, W., Lu, M., Zhang, J., Wang, M. and Cao, P. (2011) Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol. In Vitro 25, 1385-1391.